Flow cytometric analysis of Human CD66b expression on Human Peripheral Blood cells. Human Peripheral Blood cells were stained with either Mouse IgG1, κ Isotype Control (Left panel) or SDT FITC Mouse Anti-Human CD66b Antibody (Right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD66b |
Synonyms | Cell adhesion molecule CEACAM8; CD67 antigen; Carcinoembryonic antigen CGM6; Carcinoembryonic antigen-related cell adhesion molecule 8 (CEA cell adhesion molecule 8Imported); Non-specific cross-reacting antigen NCA-95; CGM6; CEACAM8 |
Location | Cell membrane |
Accession | P31997 |
Clone Number | S-3042 |
Antibody Type | Mouse mAb |
Isotype | IgG1,k |
Application | FCM |
Reactivity | Hu |
Positive Sample | Human Peripheral Blood cells |
Purification | Protein G |
Concentration | 0.2 mg/ml |
Conjugation | FITC |
Physical Appearance | Liquid |
Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
application | dilution | species |
FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD66b, also known as CEACAM8, is a cell surface glycoprotein and a member of the immunoglobulin superfamily, specifically the carcinoembryonic antigen (CEA)-like subfamily. It is a glycosylphosphatidylinositol (GPI)-anchored protein with a molecular weight of approximately 95-100 kDa. CD66b is primarily expressed on granulocytes, including neutrophils and eosinophils, and plays a significant role in cell adhesion in a calcium-independent manner. It mediates heterophilic adhesion with other CEA-related cell adhesion molecules, such as CD66c, and is particularly involved in the activation and adhesion of neutrophils. Additionally, CD66b has been implicated in various biological processes, including the regulation of eosinophil activation and the immune response in allergic diseases and parasitic infections. In cancer research, CD66b expression has been associated with prognosis in non-small cell lung cancer, with higher levels in the immune stroma linked to poorer outcomes.
Picture
Picture
FC
